Wesley Day - Concepedia

Author

Wesley Day

Vivus (United States)ORCID

Also Known As

Ismail Ajjawi, W W Day, W. Day, W. W. Day, W.W. Day, Wesley Day, Wesley W Day, Wesley W. Day

Publications

Citations

H-Index

Concepts

All Affiliations

Vivus (United States)Albert Einstein College of Medicine University of Alabama at Birmingham Medpace (United States)Pomerado Hospital

About

Wesley Day is an author at Vivus (United States) specializing in medicine, pharmacology, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	13	14	2.9K
2	Biochemistry	4	4	117
3	Health Sciences	3	3	1.4K
4	Natural Sciences	1	1	48
5	Public Health	1	1	30

Wesley Day

Publications

3.8K

Citations

H-Index

Page 1

	Year	Citations
Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial Kishore M. Gadde, David B. Allison, Donna H. Ryan, The Lancet ObesityHealth PolicyTopiramate CombinationAssociated ComorbiditiesObesity Management	2011	1K
Controlled‐Release Phentermine/Topiramate in Severely Obese Adults: A Randomized Controlled Trial (EQUIP) David B. Allison, Kishore M. Gadde, W. Timothy Garvey, Obesity NutritionBariatric SurgeryClass IiSeverely Obese AdultsCardiometabolic Risk	2011	703
Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study W. Timothy Garvey, Donna H. Ryan, Michelle Look, American Journal of Clinical Nutrition ObesityMetabolic SyndromeNutritionEnergy HomeostasisLifestyle Modification	2011	691
Prevention of Type 2 Diabetes in Subjects With Prediabetes and Metabolic Syndrome Treated With Phentermine and Topiramate Extended Release W. Timothy Garvey, Donna H. Ryan, Robert R. Henry, Diabetes Care	2013	206
Prevention of bone loss in postmenopausal women treated with lasofoxifene compared with raloxifene Michael R. McClung, Ethel S. Siris, Steve Cummings, Menopause The Journal of The North American Menopause Society	2006	109
A Phase 3, Placebo Controlled Study of the Safety and Efficacy of Avanafil for the Treatment of Erectile Dysfunction After Nerve Sparing Radical Prostatectomy John P. Mulhall, Arthur L. Burnett, Run Wang, The Journal of Urology	2012	104
A Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Avanafil in Subjects with Erectile Dysfunction Irwin Goldstein, Andrew McCullough, LeRoy Jones, The Journal of Sexual Medicine	2012	103
Gluthathione and lipid peroxidation in the aging rat Mohammed Y. H. Farooqui, Wesley Day, Daniel M. Zamorano Comparative Biochemistry and Physiology Part B Comparative Biochemistry Aging RatAgingLongevityLipid PeroxidationPhysiology	1987	101
Avanafil for the Treatment of Erectile Dysfunction: A Multicenter, Randomized, Double-Blind Study in Men With Diabetes Mellitus Irwin Goldstein, LeRoy Jones, Laurence Belkoff, Mayo Clinic Proceedings Diabetes ManagementUrologyErectile DysfunctionDiabetesDouble-blind Study	2012	85
Selectivity of Avanafil, a PDE5 Inhibitor for the Treatment of Erectile Dysfunction: Implications for Clinical Safety and Improved Tolerability Run Wang, Arthur L. Burnett, Warren Heller, The Journal of Sexual Medicine	2012	80

Page 1